Robot-assisted radical prostatectomy causes discomfort in the immediate postoperative period. This randomised controlled trial investigated if intrathecal bupivacaine/morphine, in addition to general anaesthesia, could be beneficial for the postoperative quality of recovery. One hundred and fifty-five patients were randomly allocated to an intervention group that received intrathecal 12.5 mg bupivacaine/300 lg morphine (20% dose reduction in patients > 75 years) or a control group receiving a subcutaneous sham injection and an intravenous loading dose of 0.1 mg.kg À1 morphine. Both groups received standardised general anaesthesia and the same postoperative analgesic regimen. The primary outcome was a decrease in the Quality of Recovery-15 (QoR-15) questionnaire score on postoperative day 1. The intervention group (n = 76) had less reduction in QoR-15 on postoperative day 1; median (IQR [range]) 10% (1-8 [À60% to 50%]) vs. 13% (5-24 [À6% to 50%]), p = 0.019, and used less morphine during the admission; 2 mg (1-7 [0-41 mg]) vs. 15 mg (12-20 [8-61 mg]), p < 0.001. Furthermore, they perceived lower pain scores during exertion; numeric rating scale (NRS) 3 (1-6 [0-9]) vs. 5 (3-7 [0-9]), p = 0.001; less bladder spasms (NRS 1 (0-2 [0-10]) vs. 2 (0-5 [0-10]), p = 0.001 and less sedation; NRS 2 (0-3 [0-10]) vs. 3 (2-6 [0-10]), p = 0.005. Moreover, the intervention group used less rescue medication. Pruritus was more severe in the intervention group; NRS 4 (1-7 [0-10]) vs. 0 (0-1 [0-10]), p = 0.000. We conclude that despite a modest increase in the incidence of pruritus, multimodal pain management with intrathecal bupivacaine/ morphine remains a viable option for robot-assisted radical prostatectomy.
Introduction plane block, administration of intravesical ropivacaine, suprapubic catheters and intrathecal morphine were investigated and resulted in moderate analgesic effects [2] [3] [4] [5] [6] . This emphasises the necessity for improvement of postoperative care in the first days after robot-assisted radical prostatectomy.
An ideal analgesic method has maximal benefit and few side-effects, and this is likely to be reflected in the quality of recovery. The analgesic effects of intrathecal morphine have been demonstrated to last for 20-48 h [6, 7] .
The side-effects, however, have not been studied sufficiently in this type of surgery. One of the side-effects of intrathecal morphine is urinary retention. This is relieved as a direct result of this procedure, since all patients receive a urinary catheter following surgery [8] . Moreover, bladder spasm-related discomfort may be effectively reduced by intrathecal morphine, since it reduces bladder contractions [9] . These properties of intrathecal morphine suggest that it is a potentially suitable technique for improving the quality of recovery after robot-assisted radical prostatectomy.
The aim of this study was therefore to evaluate quality of recovery after administration of intrathecal bupivacaine/ morphine following robot-assisted radical prostatectomy surgery. Besides length of stay and surgical conditions, this study investigated the positive and negative effects of intrathecal morphine. We hypothesised that, due to a reduction in pain and discomfort, intrathecal bupivacaine/ morphine would lead to improved quality of recovery on the first postoperative day compared with the control group.
Methods
This study was a single-centre, observer-and patientblinded randomised clinical trial performed in a teaching hospital and national referral centre for robot-assisted radical prostatectomy (Maasstad Hospital, Rotterdam, the Netherlands). The study was approved by the local ethics committee (Toetsingcommissie Wetenschappelijk
Onderzoek Rotterdam e.o., the Netherlands) and the
CCMO (Dutch abbreviation for Central Committee on
Research involving Human Subjects).
All patients scheduled for robot-assisted radical prostatectomy with or without pelvic lymph node dissection between October 2016 and June 2018 were eligible for participation. Exclusion criteria were: age < 18 y; contraindications to study medication (such as allergy or glomerular filtration rate < 30 ml.min À1 ); contra-indications to spinal anaesthesia (such as severe aortic stenosis, coagulation disorders, increased intracranial pressure); scheduled postoperative ICU admission; and patient refusal to participate.
Patients were informed about the study during the preoperative screening. Weeks before surgery the patients were called for further explanation, informed consent and the baseline Quality of Recovery-15 (QoR-15) questionnaire.
Patients provided written informed consent before the start of randomisation in the pre-operative holding area.
Randomisation was by the use of sealed, opaque
envelopes. An independent colleague randomised these envelopes in blocks of 10 with a 1:1 ratio to produce an equal distribution of intervention across the whole study period.
The envelopes were stacked and stored. When an included patient arrived in the holding area, the upper envelope was opened by the attending anaesthetist. The patient, surgical team, nurses on the ward and researchers were all blinded.
Only the attending anaesthetic team and the nurse in the post-anaesthesia care unit (PACU) were aware of group Patients were discharged home after a minimum of one night in hospital when they: were able to mobilise; achieve adequate pain control with oral medication; able to eat and drink; had vital signs within normal limits; and had sufficient home care.
The primary outcome was percentage decrease in QoR-15 at POD 1 from the baseline score that was established within the weeks before surgery. On POD 1, the QoR-15-questionnaire was assessed by a blinded anaesthetic nurse. Furthermore, the QoR-15 on POD 1 was analysed both as an absolute decrease and as a single score. The five subdomains of QoR-15 measurements were also analysed [10] .
The QoR-15 (range 0-150, in which 150 is the best possible outcome) is a validated questionnaire commonly used in the peri-operative setting and recommended as an outcome measure by the ESA-ESICM joint taskforce on perioperative outcome measures [11] . The QoR-15 is reported as absolute decrease, relative decrease and single score [10] . We chose the relative decrease in percentage as the primary outcome measure because population values of absolute thresholds for QoR-15 in patients undergoing robot-assisted radical prostatectomy were not available when the study was initiated. After initiation of the study, a minimal clinically important difference was defined as 8.0
and an acceptable symptom state of 118 was determined [12] .
The intra-operative secondary outcomes (duration of different stages of the anaesthesia, sufentanil and rocuronium administration, i.v. fluid administration, blood loss, pain scores and complications) were noted on a case record form that was filled in by the anaesthetic team and PACU nurse (who were unblinded) during surgery and the recovery phase. Furthermore, the attending urologist (blinded) was asked to score the surgical difficulty of the procedure on a numeric rating scale (NRS), ranging from 0 (easy) to 10 (very difficult) after surgery. The PCA system was checked electronically for total morphine consumption and bolus demands.
For the postoperative secondary outcomes, an anaesthetic nurse (blinded) visited the patients on POD 1. In addition to the QoR-15, seven items related to the potential benefits and side-effects of intrathecal morphine: physical discomfort; pain during exertion; bladder spasms; sedation; sleep; pruritus; and general satisfactionwere recorded with a NRS ranging from 0 (low or absent) to 10 (high or severe) (see also Supporting Information, Data S1).
One week after surgery, a trained medical secretary (blinded), telephoned the patient to assess the QoR-15 on postoperative day 7 (POD 7).
Additionally, 12 questions were asked regarding the hospital admission in a retrospective manner on a NRS ranging from 0 (low or absent) to 10 (high or severe, see also Supporting Information, Data S1). These 12 questions consisted of the same seven items asked on 
Results
Four hundred and fifty-nine patients were screened, of whom 12 were not included and 287 declined to participate Table 1 . The groups were comparable; only lymph node dissection was performed more often in the intervention group.
The completion rate for QoR-15 was 89.7% preoperatively, 93.5% for POD 1 and 99.4% for POD 7. Since both the pre-operative and the POD 1 QoR-15 were required to assess primary outcome, 89.6% in the intervention group and 77.2% in the control group were available for analysis of the primary outcome (Fig. 1) . , p = 0.077 at POD 1 (Fig. 2) .
The absolute decrease in QoR-15 and subdomains are presented in Table 2 . Analyses of QoR-15 subdomains showed that only the decline in 'pain' was significantly lower in the intervention group than in the control group on POD 1 ( Table 2 ). All the absolute values and individual questions of the QoR-15 are described in the Supporting Information Data S1.
Closer inspection of the domain 'pain' (range from 0 to 20, 0 = severe pain, 20 = no pain) on POD 1 showed that the number of patients with extreme pain (scores < 10) was decreased; 13 (18.3%) vs. 2 (2.8%), p = 0.002 in the intervention and control groups, respectively.
The intervention group had less pain as assessed by the NRS and consumed less opioids than the control group on POD 1 ( difference in severity of nausea or general satisfaction was detected between groups. Furthermore, no differences in laboratory results such as creatinine levels, C-reactive protein or haemoglobin values were detected (see also
Supporting Information, Data S1).
There was no significant difference in QoR-15 (including subdomains) on POD 7 (Fig. 2) . The retrospective scores of symptom severity regarding the hospital admission showed lower scores than on POD 1 in both groups. Only the difference for the severity of pruritus remained ( Table 2 ). There was no difference in the use of analgesics one week after surgery (p = 0.137); patients used no analgesics at all (33% vs. 51%), only paracetamol (62% vs. 45%) or paracetamol with the addition of nonsteroidal anti-inflammatory drugs or opioids (5% vs. 4%) for the intervention and control groups, respectively. A minority of patients felt physically limited in their activities beyond the limitations set by the urologist (16% vs. 15%, p = 1.000).
Perceived mental restrictions were similar in both groups (p = 0.347); if patients reported them, they were minor (9% vs. 6%) or moderate (1% vs. 5%). Sub-group analysis for prostatectomy with or without lymph node dissection showed similar results as the total group for morphine consumption and QoR-15 at POD 1.
Discussion
This study showed that QoR-15 decreased less in patients who received intrathecal bupivacaine/morphine than in the control group after robot-assisted radical prostatectomy. The percentage and absolute decrease between preoperative QoR-15 and postoperative 1 were different (p = 0.019 and p = 0.013) between the intervention and control groups. There were no significant differences between absolute values between the groups. A score of 118 (dashed line) is defined as acceptable symptom state [12] .
The present study showed a significant difference in patient decreases in QoR-15 between groups, but not absolute values of QoR-15. Changes relative to baseline value are preferred because it addresses individual patient changes and corrects for differences within a group [11, 13] .
Still, the difference between groups is marginal, the decrease in QoR-15 was less than estimated in the sample size calculation and the absolute scores were comparable with 'minor' or 'intermediate surgery' [12] . As such, these findings indicate that the intervention had a limited effect on the QoR-15.
A clinically important effect was found in pain reduction. The distribution of scores in the domain 'pain'
showed that the number of patients in pain was reduced, which led to a six-fold decrease in patients in severe pain in the intervention group. The current study confirmed these findings in a larger sample and added some other useful features. Firstly, bupivacaine was added to the intrathecal morphine, which prolongs the analgesic effect [14] . No disadvantages of the bupivacaine were observed, such as severe haemodynamic compromise or residual motor blockade that prevented mobilisation. Secondly, in the current study paracetamol and non-steroidal anti- The increased severity of pruritus in the intervention group is clinically relevant and in accordance with other studies [15] . This appeared not to affect the QoR-15, probably because pruritus is not included in QoR-15.
Ondansetron and dehydrobenzperidol were administered as prophylactic drugs against pruritus [16] . Remarkably, no patient requested treatment for these side-effects. The continuation of 5-HT 3 antagonists at fixed times could have further decreased the incidence and severity of pruritus, but this aspect of management was not included in the study protocol [17] . Additionally, management of patients' expectations by providing information and explanation may have limited this discomfort, since unexpected symptoms may be perceived as more severe [18] . Postoperative nausea was not increased by the use of intrathecal morphine, even though this is a well-known side-effect [19] .
This could be explained to some extent by the prophylactic use of ondansetron, dehydrobenzperidol and the male sex of the study population [16] .
Our hypothesis that intrathecal bupivacaine would lead to increased laparoscopic workspace due to motor block is not supported by this study. Even though we were unable to measure true laparoscopic workspace in this study, the surrogate markers did not differ. Nevertheless, the addition of bupivacaine might have the beneficial effects of producing analgesia before the onset of the intrathecal morphine and prolonging duration of action [14] , but this was not investigated in the present study.
The most feared side-effect of intrathecal morphine, late respiratory depression, did not occur in any patients.
Incidence is difficult to estimate, since the definition of respiratory depression varies from a SaO 2 < 94% and/or PaCO 2 > 6 kPa to a respiratory rate < 6 breaths per min [20] .
Most reported cases of late respiratory depression with the use of < 500 lg intrathecal morphine required no intervention [19] . Therefore, we did not employ any specific monitoring for this complication, since clinically-relevant respiratory depression is unlikely to occur more often with low-dose intrathecal morphine (< 500 lg) than with PCA morphine [19, 21] . Sedatives and opioids (other than as needed in PCA) were contra-indicated on the night after surgery due to the potential to interact with intrathecal morphine and cause severe respiratory depression [22] .
This study has several limitations. One limitation is the protocol violation in five patients who received an i.v.
loading dose of morphine in addition to the intrathecal In conclusion, this study showed that a single shot of intrathecal bupivacaine/morphine reduced the decrease in quality of recovery in the first 24 h after robot-assisted radical prostatectomy in a limited manner.
There were important reductions in opioid consumption, sedation, bladder spasms, number of patients with severe pain and need for rescue medication. Despite a modest increase in the incidence of pruritus, multimodal pain management with intrathecal bupivacaine/morphine remains a viable option for robot-assisted radical prostatectomy.
